Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
BA.5.2.47ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
ED.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BN.1.2.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
CQ.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
CH.1.1.24ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.5.2.22ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BN.1.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BN.1.3.7ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
LB.1.3.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BQ.1.1.13ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.2.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BR.2.1ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.1.5.28ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
GA.2ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BQ.1.1.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BQ.1.1.10ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.1.5.80ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.2.3.10ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
AY.121.1 (Delta)ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BN.1.3.4ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.36ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.1.5.60ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBB.1.5.90ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
EG.6ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
XBF.5ECharité-EATATTGCAGCAGTACGCACACA2245.452638126360R-4212.07Germany
BA.2.62NSC2CCTTGTGTGGTCTGCATGAGTTTAG25482955429530R-4245.4US
BA.2.86.4NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
AY.4.10 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.177.26NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2 (Omicron)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
AY.121.1 (Delta)NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.160.26NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
B.1.1.371NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
GM.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BT.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.76NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.4.6NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.5.6.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.5.1.10NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BS.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.5.1.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BQ.1.18NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BN.1.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.5.9NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BL.1NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
CQ.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.51NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.3.18NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.3.2NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
BA.2.65NNIID-JP-NAAATTTTGGGGACCAGGAAC20452912529144F-4248.57Japan
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used